11/12/2025
✨ Big news from the FDA! ✨
The black box warning has been removed from estrogen products — a major step forward for women’s health.
We’ve come a long way since the Women’s Health Initiative (WHI). We now understand that, for many women who start estrogen close to the time of menopause, there is no increased risk of cardiovascular disease, dementia, or breast cancer.
Today’s hormone therapy uses different formulations and routes than what was studied in the WHI. While this label change doesn’t come with new data, it does mean that women will no longer receive overly broad warnings that may not apply to them.
As always, it’s important to have open, individualized conversations with your practitioner about the benefits, risks, and side effects of hormone therapy.
When women have accurate information, they make informed and empowered choices. 💪💗